NCT00750334终止1 期
A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)
Genzyme, a Sanofi Company3 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 3
- 主要终点
- Maximum Tolerated dose levels
研究概览
简要总结
This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide signed, written informed consent.
- •Be at least 18 years old.
- •Have a pathologically confirmed MDS and score according to the IPSS at study entry. Pathologic confirmation is the responsibility of the investigator.
- •Have been treated previously for MDS as follow: a.Patients must have had at least 1, but no more than 2, prior treatment regimens; b.Patients must not have refractory (i.e., disease progression or no evidence of response while on treatment) to more than 1 prior treatment regimen.
- •Have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Be able to comply with study procedures and follow-up examinations.
- •Have adequate hepatic and renal function.
- •Be non-fertile or agree to use birth control during the study through the end of the last treatment visit and at least 90 days after.
排除标准
- •Have had a readjustment of dose and/or schedule of erythropoietin, granulocyte colony stimulating factor(G-CSF) or other growth factors within 8 weeks prior to the first dose of oral clofarabine.
- •Have had any other chemotherapy or any investigational therapy for MDS within 4 weeks of the first dose of oral clofarabine.
- •Have not recovered to ≤ Grade 2 in severity of any drug-related non-hematologic toxicity prior to the first dose of oral clofarabine.
- •Have an uncontrolled systemic fungal, bacterial, viral or other infection. Have a history of serious disease involving the heart.
- •Have a clinically significant cardiac assessment at screening or a known family history QT prolongation.
- •Currently uses a medication known to prolong the QT interval.
- •Have had any prior treatment with clofarabine (IV or oral).
- •Have had a diagnosis of another malignancy, unless the patient has been disease free for at least 3 years after completing curative intent therapy except for the following: a. Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment or the condition has been completed. b. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
- •Have prior positive test for the human immunodeficiency virus (HIV).
- •Have gastrointestinal disease or prior surgery, which may affect the ability of the patient to absorb oral clofarabine.
- •Is currently participating in another concurrent investigational protocol that is not restricted to data and/or sample collection for patient demographic and/or disease purposes.
研究组 & 干预措施
Part A
Experimental
clofarabine Dose Escalation
干预措施: clofarabine (Drug)
Part B
Experimental
Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.
干预措施: clofarabine (Drug)
结局指标
主要结局
Maximum Tolerated dose levels
时间窗: First Cycle
次要结局
- PK profile(After MTD is established)
- Food effect on profile(After MTD is established)
- Activity of clofarabine in this dosing regimen(Duration of Study)
研究者
研究点 (3)
Loading locations...
相似试验
撤回
1 期
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaLeukemiaNCT00800566M.D. Anderson Cancer Center
终止
1 期
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaCancerChronic Myelomonocytic LeukemiaNCT00708721University of Utah11
已完成
1 期
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic LeukemiaAcute Lymphoid Leukemia RelapseAcute Lymphoid Leukemia Relapse After Bone Marrow TransplantNCT01279096University Hospital, Lille20
终止
1 期
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasAcute Promyelocytic LeukemiaMyeloproliferative DisordersAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeAcute LeukemiaChronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaMyelofibrosisJuvenile Myelomonocytic LeukemiaNCT00852709Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35
已完成
1 期
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHLNon Hodgkin's LymphomaNCT00477945Indiana University School of Medicine18